1. Scrip
  2. >>Business

Takeda Sheds Multilab In Brazil As Strategic Priorities Shift

 
• By Ian Haydock

Takeda is selling its Multilab operation in Brazil, in a reversal of a deal to buy the mid-sized company around six years ago to bolster its position and generic/OTC portfolios in the country.

BrazilianPill_1200x675
TAKEDA SELLS MULTILAB AS PRIORITIES SHIFT • Source: Shutterstock

In a reversal of a past acquisition, Takeda Pharmaceutical Co. Ltd. is to fully divest all its shares and assets in Multilab Indústria e Comércio de Produtos Farma in Brazil to Novamed, part of the Brazilian NC Group that also owns several of the other large pharma firms in the country such as EMS and Germed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.